TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02817529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonica
Description: The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RC-Cornet
Description: RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
Study: NCT03833193

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Radiation: Hypofractionated radiotherapy at 3Gy/f
Study: NCT02591498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Study: NCT04330313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction
Description: Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot pack
Description: The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
Study: NCT04059536

Intervention type: DEVICE
Intervention: Roxwood Anchoring Catheters
Description: Anchoring catheters

Intervention type: DRUG
Intervention: Acetylsalicylic Acid
Description: Oral Tablet

Intervention type: DRUG
Intervention: Heparin
Description: Intravenous Injection
Study: NCT01708785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single food Cue Exposure Treatment
Description: Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single food Cue Exposure Treatment
Description: Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple food Cue Exposure Treatment
Description: Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multiple food Cue Exposure Treatment
Description: Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement - Enhanced Cue Exposure Treatment
Description: Subjects will take random additional tastes of the food during cue exposure treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial Reinforcement - Enhanced Cue Exposure Treatment
Description: Subjects will take random additional tastes of the food during cue exposure treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement -Consistent Cue Exposure Treatment
Description: Subjects will consistently take the same tastes of the food during cue exposure treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial Reinforcement -Consistent Cue Exposure Treatment
Description: Subjects will consistently take the same tastes of the food during cue exposure treatment.
Study: NCT00260962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day Hospital
Description: Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Day Hospital
Description: Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
Study: NCT03207035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block
Description: Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block
Description: Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
Study: NCT01756170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study: NCT00015834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT01613846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib+Pazopanib
Description: Sorafenib (first-line) followed by Pazopanib (second-line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib+Sorafenib
Description: Pazopanib (first-line) followed by Sorafenib (second-line)
Study: NCT02980861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
Study: NCT01667419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
Study: NCT02663544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited dairy diet
Description: Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet
Description: Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Description: Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
Study: NCT05377801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-dimensional fall prevention intervention program for 12 weeks
Description: The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
Study: NCT00097656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-center, randomized, controled periodontal therapy
Description: periodontal therapy
Study: NCT01814709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Oral doses of GDC-0032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Oral doses of GDC-0032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral doses of Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral doses of Rifampin
Study: NCT03641404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergothioneine
Description: Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo. Study control (99% microcrystalline cellulose)
Study: NCT02757716

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
Study: NCT03472261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Dysport

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity orthoses
Description: Twister

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Specific exercises for pronation deformity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Specific exercises for pronation deformity
Study: NCT00748904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 20 grams titrate to 2-3 bowel movements in one day
Study: NCT00673530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence based clinical nutrition concept
Description: The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: care as usual
Description: Unchanged treatment of hospital patients without interference by the study.
Study: NCT02147561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
Study: NCT04721080

Intervention type: OTHER
Intervention: Functional Outcome Measurements
Description: Dyspnea Exercise capacity Quality of life assessment

Intervention type: OTHER
Intervention: Functional Outcome Measurements
Description: Dyspnea Exercise capacity Quality of life assessment
Study: NCT02829190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI),
Description: Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI),
Description: Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI),
Description: Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI),
Description: Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
Study: NCT03835949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ004309
Description: Antibody to CD73

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Humanized monoclonal antibody to PD-L1
Study: NCT00775008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: electronic health information
Description: Participants will receive weight loss information via 1 of 2 different mediums.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic health information
Description: Participants will receive weight loss information via 1 of 2 different mediums.
Study: NCT00616538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiceram(r)
Description: Topical barrier repair emulsion cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 0.05%
Description: Topical mid-strength steroid
Study: NCT04304638

Intervention type: RADIATION
Intervention: radiation or chemo-radiation
Description: standard treatment for stage III lung cancer

Intervention type: RADIATION
Intervention: radiation or chemo-radiation
Description: standard treatment for stage III lung cancer

Intervention type: DRUG
Intervention: EGFR-TKI Inhibitor
Description: the standard treatment for stage IV lung cancer with EGFR mutation

Intervention type: DRUG
Intervention: EGFR-TKI Inhibitor
Description: the standard treatment for stage IV lung cancer with EGFR mutation
Study: NCT01223742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACETYL-L-CARNITINE
Description: 2 g acetylcarnitine taken orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice per day
Study: NCT01727024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium via Respimat® device once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol via Breezhaler® device once a day
Study: NCT01852396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroclavicular block
Description: Retroclavicular approach ultrasound guided regional anesthesia
Study: NCT00811096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole
Description: 2gms, p.o. q.d. for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine
Study: NCT03294564

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will consist of 0.5mL of saline.
Study: NCT02899572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sexology consultation
Description: a sexology consultation is planned in the 15 days after inclusion
Study: NCT00773539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using an open irrigated tip catheter
Description: transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using a closed irrigated tip catheter
Description: transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using a cryoballoon
Description: transseptal PVI using the cryoballoon from CRYOCATH
Study: NCT01600534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
Study: NCT01917253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Device for peripheral vein cannulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Catheters for peripheral vein cannulation
Study: NCT00822549

Intervention type: DRUG
Intervention: intravenous morphine titration
Description: intravenous morphine titration
Study: NCT02523144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Description: 70mg/kg chloral hydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 3mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flavored placebo syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flavored placebo syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flavored placebo syrup
Study: NCT02567604

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: at least three focus groups lasting approximately one hour
Study: NCT02416622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-CB-hRS1
Description: adeno-associated virus vector expressing retinoschisin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-CB-hRS1
Description: adeno-associated virus vector expressing retinoschisin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-CB-hRS1
Description: adeno-associated virus vector expressing retinoschisin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-CB-hRS1
Description: adeno-associated virus vector expressing retinoschisin
Study: NCT00498290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery (ERAS) protocol
Description: An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: control
Description: normal recovery protocol as usually
Study: NCT04308967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercises
Description: Three-stage progressive balance exercises will be applied.